YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

Phase 2

Completed

Conditions: Binge-Eating Disorder

Interventions: Drug: Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
Other: Placebo

First Posted Date: 2018-05-29

Last Posted Date: 2024-04-03

Lead Sponsor: Yale University

Target Recruit Count: 89

Registration Number: NCT03539900

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

CB1R in Synthetic Psychoactive Cannabinoids

Not Applicable

Active, not recruiting

Conditions: Drug Dependence

Interventions: Other: [11-C]OMAR

First Posted Date: 2018-05-29

Last Posted Date: 2024-01-24

Lead Sponsor: Yale University

Target Recruit Count: 15

Registration Number: NCT03539575

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants

Completed

Conditions: Thoracic Effusion
Pleural Effusion

Interventions: Drug: Novel Oral Anti-Coagulants

First Posted Date: 2018-05-24

Last Posted Date: 2023-10-13

Lead Sponsor: Yale University

Target Recruit Count: 590

Registration Number: NCT03535883

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Nutrition and Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Fermented Soy
Other: Placebo

First Posted Date: 2018-05-22

Last Posted Date: 2021-05-26

Lead Sponsor: Yale University

Target Recruit Count: 19

Registration Number: NCT03532308

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
South County Hospital, Wakefield, Rhode Island, United States
🇺🇸
Yale New Haven Health- Lawrence + Memorial Hospital, New London, Connecticut, United States

Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET

Not Applicable

Completed

Conditions: Opiate Dependence
Cocaine Dependence

Interventions: Diagnostic Test: 11UCB-J PET Scan

First Posted Date: 2018-05-17

Last Posted Date: 2024-07-16

Lead Sponsor: Yale University

Target Recruit Count: 41

Registration Number: NCT03527485

Locations: 🇺🇸
CT Mental Health Center, New Haven, Connecticut, United States

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Early Phase 1

Terminated

Conditions: Metastatic Melanoma

Interventions: Drug: Tumor Infiltrating Lymphocytes
Drug: Nivolumab and Ipilimumab

First Posted Date: 2018-05-16

Last Posted Date: 2022-07-25

Lead Sponsor: Yale University

Target Recruit Count: 6

Registration Number: NCT03526185

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome

Withdrawn

Conditions: Diabetes Mellitus
Intraductal Papillary Mucinous Neoplasm
McCune-Albright Syndrome
Fibrous Dysplasia

Interventions: Procedure: Hyperinsulinemic Euglycemic Clamp and 2H20
Procedure: Hyperglycemic Clamp
Diagnostic Test: Oral Glucose Tolerance Test

First Posted Date: 2018-05-09

Last Posted Date: 2019-09-04

Lead Sponsor: Yale University

Registration Number: NCT03520153

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.

Early Phase 1

Terminated

Conditions: Obesity, Childhood
Neural Development

Interventions: Drug: Liraglutide

First Posted Date: 2018-04-18

Last Posted Date: 2024-07-16

Lead Sponsor: Yale University

Target Recruit Count: 13

Registration Number: NCT03500484

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer
Advanced Melanoma
Renal Cell Carcinoma

Interventions: Drug: APX005M
Drug: Cabiralizumab
Drug: Nivolumab

First Posted Date: 2018-04-18

Last Posted Date: 2024-07-03

Lead Sponsor: Yale University

Target Recruit Count: 42

Registration Number: NCT03502330

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Vacuum vs Manual Drainage During Unilateral Thoracentesis

Not Applicable

Completed

Conditions: Pleural Effusion
Pleural Diseases
Thoracic Diseases

Interventions: Device: Vacuum Bottle Drainage

First Posted Date: 2018-04-12

Last Posted Date: 2023-07-14

Lead Sponsor: Yale University

Target Recruit Count: 100

Registration Number: NCT03496987

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy